Literature DB >> 2140092

An assessment of the accuracy of NovoPen 1 delivery after prolonged use.

D Gordon1, M Wilson, K R Paterson, C G Semple.   

Abstract

Forty-five NovoPen 1 injection devices have been assessed for accuracy of insulin delivery. Twenty-six pen-injectors had been returned either because the device had developed structural faults or the patients had experienced unexpected deterioration in diabetic control. Twelve of these pen-injectors were unusable. The remaining 14 pen-injectors ('faculty pen-injectors') were assessed by measuring the weight of insulin solution delivered in each of 10 depressions of the plunger and compared with similar measurements from 10 unused pen-injectors ('new pen-injectors') and 9 pen-injectors ('used pen-injectors') which had been used uneventfully for greater than 3 years. New pen-injectors delivered insulin solution with an accuracy (median error) of 2.8% and reproducibility (median SD) of 2.0%. Used pen-injectors had an accuracy of 2.3% and reproducibility of 3.5%. The 14 suspect pen-injectors ('faculty pen-injectors') demonstrated an accuracy of 2.8% with reproducibility of 4.0%. The reduction in reproducibility was due to faults in 4 pen-injectors, 2 of which consistently delivered less insulin than expected, while a further two pen-injectors were intermittently inaccurate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140092     DOI: 10.1111/j.1464-5491.1990.tb01407.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  4 in total

1.  Insulin pens. Is delivery sacrificed to improve patient compliance?

Authors:  D Gordon
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 2.  A review of 20 years' experience with the NovoPen family of insulin injection devices.

Authors:  Jørn Rex; Klaus H Jensen; Simon A Lawton
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes.

Authors:  M G Gnanalingham; P Newland; C P Smith
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

Review 4.  A review of 25 years' experience with the NovoPen family of insulin pens in the management of diabetes mellitus.

Authors:  Jacob Hyllested-Winge; Klaus H Jensen; Jørn Rex
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 3.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.